UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Teleflex Incorporated (NYSE:TFX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Teleflex Incorporated (NYSE:TFX - Free Report) by 2.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 333,260 shares of the medical technology company's stock after purchasing an additional 7,379 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.72% of Teleflex worth $82,422,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Glenmede Trust Co. NA boosted its holdings in Teleflex by 5.9% in the third quarter. Glenmede Trust Co. NA now owns 4,481 shares of the medical technology company's stock valued at $1,108,000 after purchasing an additional 249 shares in the last quarter. Townsquare Capital LLC acquired a new position in shares of Teleflex during the 3rd quarter worth $200,000. BNP Paribas Financial Markets increased its stake in Teleflex by 14.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 64,498 shares of the medical technology company's stock valued at $15,952,000 after purchasing an additional 7,907 shares in the last quarter. FMR LLC lifted its stake in Teleflex by 70.1% in the 3rd quarter. FMR LLC now owns 269,490 shares of the medical technology company's stock valued at $66,650,000 after buying an additional 111,086 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of Teleflex by 10.9% in the third quarter. Daiwa Securities Group Inc. now owns 11,295 shares of the medical technology company's stock valued at $2,793,000 after buying an additional 1,106 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.

Teleflex Stock Performance

Shares of TFX traded down $6.18 during trading hours on Tuesday, hitting $188.13. The company's stock had a trading volume of 518,652 shares, compared to its average volume of 383,072. The company has a market cap of $8.74 billion, a price-to-earnings ratio of 37.27, a PEG ratio of 1.99 and a beta of 1.16. The business has a 50 day simple moving average of $218.89 and a two-hundred day simple moving average of $222.26. Teleflex Incorporated has a 52-week low of $185.27 and a 52-week high of $257.85. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.38 by $0.11. The firm had revenue of $764.40 million for the quarter, compared to analysts' expectations of $768.68 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company's revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period last year, the firm earned $3.64 earnings per share. On average, equities analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.72%. The ex-dividend date of this dividend is Friday, November 15th. Teleflex's dividend payout ratio is currently 27.04%.

Analyst Upgrades and Downgrades

Several research firms have commented on TFX. Mizuho cut their price objective on Teleflex from $275.00 to $250.00 and set a "neutral" rating on the stock in a research report on Friday, November 1st. Truist Financial reaffirmed a "hold" rating and set a $227.00 target price (down from $255.00) on shares of Teleflex in a report on Monday, November 4th. Needham & Company LLC restated a "hold" rating on shares of Teleflex in a research note on Friday, November 1st. Royal Bank of Canada decreased their price target on shares of Teleflex from $275.00 to $245.00 and set an "outperform" rating for the company in a report on Friday, November 1st. Finally, StockNews.com upgraded Teleflex from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Teleflex currently has a consensus rating of "Moderate Buy" and an average price target of $259.25.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.